FindTrial
Sign In

IDO1 inhibitor INCB024360

DRUG2 trials

Sponsors

Roswell Park Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

GlioblastomaGlioblastoma MultiformeRecurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity CancerStage IA Fallopian Tube CancerStage IA Ovarian Epithelial CancerStage IA Primary Peritoneal Cavity Cancer

Phase 1

Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
WithdrawnNCT01982487
Roswell Park Cancer InstituteRecurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer +30
Start: 2013-12-31Updated: 2013-12-18
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
TerminatedNCT03707457
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsGlioblastoma, Glioblastoma Multiforme
Start: 2019-03-22End: 2020-06-18Updated: 2020-07-02